About ZGBiotech
ZGBiotech is a Healthcare company based in Shanghai (China) founded in 2017. CDMO focused on drug development, analytical, formulation, and quality testing services. It operates in the Healthcare and Industrial Goods & Manufacturing sectors. ZGBiotech has raised $235.75 million across 4 funding rounds from investors including Qiming Venture Partners, Goldman Sachs Asset Management and Sofina. Its focus areas include Retail, Contract Manufacturers, Chemicals and Diversified. Its competitors include OBiO Technology, Shenzhen Hepalink Pharmaceutical and Chime Biologics; 2 of its 3 listed competitors have raised funding.
Company details
ZGBiotech was founded in 2017 and is based in Shanghai, China. Operations are centered on the biotechnology sector as a contract development and manufacturing organization. Analytical development, formulation processes, and quality testing services are offered to support drug development projects. These capabilities are utilized by pharmaceutical partners for regulatory compliance and product advancement in the region.
- Headquarters Shanghai, China
- SectorsHealthcareIndustrial Goods & Manufacturing
- Email••••••••
- Phone•••• ••••
- Website zgbiotech.com
- Social LinkedIn
- Total Equity Funding$235.75M (USD)
in 4 rounds
- Latest Funding Round$14.75M (USD), Series C
Aug 2022
- InvestorsQiming Venture Partners
& 15 more
Funding Insights of ZGBiotech
ZGBiotech has successfully raised a total of $235.75M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $14.75 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $235.75M
- Total Rounds 4
- Last Round Series C — $14.75M
- First Round $51M
(Mar 2020)
- Investors Count 16
All 4 funding rounds of ZGBiotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2022 | $14.75M | Series C | – | Qiming Venture Partners | |
| Jan 2022 | $100M | Series C | – | Sofina, Goldman Sachs Investment Partners | |
| Mar 2021 | $70M | Series B | – | IDG Capital, Qiming Venture Partners | |
| Mar 2020 | $51M | Series A | – | LYFE Capital |
16 investors in total: 16 institutional.
Investors in ZGBiotech
ZGBiotech has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include Qiming Venture Partners, Goldman Sachs Asset Management and Sofina.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are provided by Sofina to emerging companies. | sofinagroup.com | Brussels, Belgium | ||
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Venture capital investments are directed toward multiple sectors. | 2006 | qimingvc.com | Shanghai, China | |
Venture capital firm | idgcapital.com | New York, United States | ||
| cowincapital.com.cn | ||||
| gtcap.cn | ||||
LYFE Capital is recognized as a premier healthcare investment platform. | lyfecapital.com | Menlo Park, USA | ||
Investments are provided by GP Capital to financial services companies. | gpcapital.com.cn | Shanghai, China | ||
Venture capital investments are provided by CASH Capital in technology sectors. | 2011 | cashcapital.cn | Beijing, China | |
Tech startups are invested in by this venture capital firm. | kipvc.cn | Singapore, Singapore |
Investor details for ZGBiotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ZGBiotech
3 dated milestones of ZGBiotech across 5 years, from founding to its latest funding, stage changes and deals.
- Founded ZGBiotech is founded.
- Funding First funding round of $51.0M.
- Funding Latest funding round, Series C, of $14.7M.
Competitors of ZGBiotech
ZGBiotech has 3 listed competitors in our database, 2 of them funded. They include OBiO Technology, Shenzhen Hepalink Pharmaceutical and Chime Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| obiosh.com | 2013 | Shanghai, China | $87.09M | OBiO Technology is engaged in cell and gene therapy solutions. | ||
| hepalink.com | 1998 | Shenzhen, China | Heparin Sodium API and derivatives are manufactured for global markets. | |||
| chimebiologics.com | 2013 | Wuhan, China | $315M | Biopharma contract development and manufacturing services are provided. |
Detailed competitors of ZGBiotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Zgbiotech
Complete news archive for ZGBiotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ZGBiotech
ZGBiotech was founded in 2017 and raised its 1st funding round 3 years after it was founded.
ZGBiotech is headquartered in Shanghai, China.
ZGBiotech is a funded company, having raised a total of $235.75M across 4 funding rounds to date. The company's 1st funding round was a Series A of $51M, raised on Mar 2020.
ZGBiotech was founded in 2017 and is based in Shanghai, China. Operations are centered on the biotechnology sector as a contract development and manufacturing organization. Analytical development, formulation processes, and quality testing services are offered to support drug development projects. These capabilities are utilized by pharmaceutical partners for regulatory compliance and product advancement in the region.
ZGBiotech's top competitors include OBiO Technology, Chime Biologics and Shenzhen Hepalink Pharmaceutical.
ZGBiotech has 16 investors. Key investors include Qiming Venture Partners, Goldman Sachs Asset Management, Sofina, Novo Holdings, and IDG Capital.